CVS

CVS HEALTH Corp

$104.47 +0.14 (+0.13%) At close · Jul 8

Market Cap

$133.30B

1,275,927,307

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$402.07B +7.8%

FY2025

Net Income

$1.77B -61.7%

FY2025

Gross Margin

15.45% -0.8pp

FY2017

Operating Margin

1.16% -1.1pp

FY2025

Diluted EPS

$1.39 -62%

FY2025

Operating Cash Flow

$10.64B +16.8%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenue	+7.6%	+8.4%	+10.1%	—	$407.91B	$402.07B	$372.81B	$357.78B	$322.47B	$292.11B	$268.71B	$256.78B	$194.58B	$184.77B	$177.53B	$153.29B	$139.37B	$126.76B	$123.13B	$107.1B	$96.41B	$98.73B
Net Interest Income	—	—	—	—	—	—	—	—	—	—	$0	$0	—	-$1.04B	-$1.06B	-$838M	-$600M	-$509M	-$557M	-$584M	-$536M	-$525M
Premiums Earned (Net)	+16.5%	+14.2%	—	—	$135.72B	$134.75B	$122.9B	$99.19B	$85.33B	$76.13B	$69.36B	$63.12B	$8.18B	—	—	—	—	—	—	—	—	—
Cost of Revenue	+4.0%	+6.2%	+5.7%	—	$225.55B	$221.17B	$206.29B	$217.1B	$196.89B	$175.8B	$163.98B	$158.72B	$156.45B	$156.22B	$148.67B	$126.76B	$114B	$102.98B	$100.63B	$86.54B	$76.16B	$78.35B
Gross Profit	+4.0%	+4.9%	—	—	—	—	—	—	—	—	—	—	—	$28.55B	$28.86B	$26.53B	$25.37B	$23.78B	$22.51B	$20.56B	$20.26B	$20.38B
Gross Margin	—	—	—	—	—	—	—	—	—	—	—	—	—	15.45%	16.26%	17.31%	18.2%	18.76%	18.28%	19.2%	21.01%	20.64%
Amortization of Intangibles	+3.0%	-3.3%	+12.5%	—	$1.92B	$1.98B	$2.03B	$1.91B	$1.81B	$2.26B	$2.34B	$2.44B	$1B	$817M	$795M	$611M	$518M	$494M	—	—	—	—
Depreciation & Amortization	+2.7%	+0.7%	+8.2%	—	$4.57B	$4.61B	$4.6B	$4.37B	$4.25B	$4.51B	$4.44B	$4.37B	$2.72B	$2.48B	$2.48B	$2.09B	$1.93B	$1.87B	$1.75B	$1.57B	$1.47B	$1.39B
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	$215M	$215M	$215M	—	—	—	—	—	—	—	—
Total Operating Expenses	+21.9%	+15.1%	+9.2%	—	—	—	—	—	—	—	—	$33.54B	$18.99B	$19.03B	$18.52B	$17.07B	$16.57B	$15.75B	$15.28B	$14.23B	$14.09B	$13.94B
Total Costs & Expenses	+8.1%	+9.3%	—	—	$401.94B	$397.41B	$364.29B	$344.03B	$314.72B	$278.92B	$254.8B	$244.79B	$190.56B	—	—	—	—	—	—	—	—	—
Operating Income	-15.6%	-19.6%	-6.8%	—	$5.97B	$4.66B	$8.52B	$13.74B	$7.75B	$13.19B	$13.91B	$11.99B	$4.02B	$9.52B	$10.34B	$9.45B	$8.8B	$8.04B	$7.23B	$6.33B	$6.17B	$6.44B
Operating Margin	—	—	—	—	—	1.16%	2.28%	3.84%	2.4%	4.52%	5.18%	4.67%	2.07%	5.15%	5.82%	6.17%	6.31%	6.34%	5.87%	5.91%	6.39%	6.52%
EBITDA	-8.2%	-12.8%	-2.2%	—	$10.53B	$9.27B	$13.11B	$18.11B	$11.99B	$17.71B	$18.35B	$16.36B	$6.74B	$12B	$12.81B	$11.55B	$10.73B	$9.91B	$8.98B	$7.9B	$7.63B	$7.83B
Interest Expense	+10.9%	+1.4%	+13.8%	—	$3.11B	$3.12B	$2.96B	$2.66B	$2.29B	$2.5B	$2.91B	$3.04B	$2.62B	$1.06B	$1.08B	$859M	$615M	$517M	$561M	$588M	$539M	—
Interest Income	+11.9%	+39.3%	—	—	—	—	—	—	—	—	—	—	—	$21M	$20M	$21M	$15M	$8M	$4M	$4M	$3M	—
Other Non-Operating Income	-12.8%	-11.5%	—	—	$116M	$112M	$99M	$88M	$169M	$182M	$206M	$124M	$4M	—	—	—	—	—	—	—	—	—
Pretax Income	-27.6%	-26.2%	-13.0%	—	$3.46B	$2.14B	$6.15B	$11.17B	$5.63B	$10.42B	$9.77B	$9B	$1.41B	$8.27B	$8.64B	$8.62B	$7.68B	$7.53B	$6.32B	$5.75B	$5.63B	$5.91B
Income Tax	-34.7%	-30.8%	-19.1%	—	$554M	$408M	$1.56B	$2.81B	$1.46B	$2.52B	$2.57B	$2.37B	$2B	$1.64B	$3.32B	$3.39B	$3.03B	$2.93B	$2.44B	$2.26B	$2.19B	$2.21B
Net Income	-24.7%	-24.4%	-10.3%	—	$2.94B	$1.77B	$4.61B	$8.34B	$4.15B	$7.91B	$7.18B	$6.63B	-$594M	$6.62B	$5.32B	$5.24B	$4.64B	$4.59B	$3.88B	$3.46B	$3.43B	$3.7B
Net Margin	—	—	—	—	—	0.44%	1.24%	2.33%	1.29%	2.71%	2.67%	2.58%	-0.31%	3.58%	3%	3.42%	3.33%	3.62%	3.15%	3.23%	3.55%	3.74%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	-$29M	-$40M	-$28M	$24M	$16M	-$12M	$13M	-$3M	-$2M	$1M	$2M	$2M	$0	$0	-$2M	-$4M	-$3M	—
Net Income Available to Common Stockholders	—	—	-10.3%	—	$2.93B	$1.77B	$4.61B	$8.34B	—	—	—	—	—	—	—	$5.24B	$4.64B	$4.59B	$3.88B	$3.46B	—	$3.7B
Comprehensive Income	+10.1%	-21.2%	-7.7%	—	$3.07B	$2.29B	$4.79B	$9.31B	$1.72B	$7.46B	$7.57B	$7.55B	-$320M	$6.76B	$5.37B	$5.1B	$4.58B	$4.62B	$3.87B	—	—	—
EPS (Basic) USD/shares	-23.8%	-23.9%	-11.3%	—	—	$1.40	$3.67	$6.49	$3.16	$6.00	$5.48	$5.10	-$0.57	$6.47	$4.93	$4.66	$3.98	$3.77	$3.05	$2.59	$2.51	$2.58
EPS (Diluted) USD/shares	-23.8%	-23.9%	-11.3%	$6.24 – $6.44	—	$1.39	$3.66	$6.47	$3.14	$5.95	$5.46	$5.08	-$0.57	$6.44	$4.90	$4.63	$3.96	$3.74	$3.03	$2.57	$2.49	$2.55
Shares Outstanding (Basic Avg) shares	-1.2%	-0.7%	+1.3%	—	—	1.27B	1.26B	1.29B	1.31B	1.32B	1.31B	1.3B	1.04B	1.02B	1.07B	1.12B	1.16B	1.22B	1.27B	1.34B	1.37B	1.43B
Shares Outstanding (Diluted Avg) shares	-1.3%	-0.7%	+1.2%	—	—	1.27B	1.26B	1.29B	1.32B	1.33B	1.31B	1.31B	1.04B	1.02B	1.08B	1.13B	1.17B	1.23B	1.28B	1.35B	1.38B	1.45B

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $41.64B in buybacks, $32.97B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

EV/EBIT

—

P/E (TTM)

45.82×

Healthcare Plans median 39.95×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Health Services Segment	$190,425,000,000	$173,605,000,000	$186,843,000,000	$169,576,000,000	$153,892,000,000	—	—	—
Health Care Benefits Segment	$143,354,000,000	$130,665,000,000	$105,646,000,000	$91,350,000,000	$82,119,000,000	$75,467,000,000	$69,604,000,000	$8,962,000,000
Pharmacy and Consumer Health Segment	$139,367,000,000	$124,500,000,000	$116,763,000,000	$108,596,000,000	$101,620,000,000	—	—	—
Pharmacy Services Segment	—	—	—	$169,236,000,000	$153,022,000,000	$141,938,000,000	$141,491,000,000	$134,736,000,000
Retail Long Term Care Segment	—	—	—	$106,594,000,000	$100,105,000,000	$91,198,000,000	$86,608,000,000	$83,989,000,000
Corporate And Other	—	—	—	—	—	—	$512,000,000	$606,000,000

By Product & Service (USD)

Component	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Product	$249,908,000,000	$231,521,000,000	$245,138,000,000	$226,616,000,000	$203,738,000,000	$190,688,000,000	$185,236,000,000	$183,910,000,000
Service	$15,175,000,000	$16,239,000,000	$12,293,000,000	$9,683,000,000	$11,042,000,000	$7,856,000,000	$7,407,000,000	$1,825,000,000
Front Store Revenue	—	—	—	—	—	—	$19,422,000,000	$19,055,000,000
Pharmacy Revenue	—	—	—	—	—	—	$165,899,000,000	$164,845,000,000
Premiums	—	—	—	—	—	—	$63,122,000,000	$8,184,000,000
Product And Service Other	—	—	—	—	—	—	$7,322,000,000	$1,835,000,000

Key facts CIK 64803 CUSIP 126650100 13F (30d) 153 filings 88 filers Visit website Investor relations